Table 6.
Frequency of CNR1 polymorphisms in study and control groups.
| A3813G (rs12720071) | P (chi2) | A4895G (rs806368) | P (chi2) | |||||
|---|---|---|---|---|---|---|---|---|
| A/A | A/G | G/G | T/T | C/T | C/C | |||
| PCOS + NAFLD | 64.41% (38) | 68.42% (13) | 50% (13) | 0.35 (2.04) | 58.82% (40) | 57.69% (15) | 87.5% (7) | 0.27 (2.6) |
| PCOS − NAFLD | 35.59% (21) | 31.58% (6) | 50% (13) | 41.18% (28) | 42.31% (11) | 12.5% (1) | ||
| Control + NAFLD | 48.48% (32) | 28.57% (4) | 66.67% (4) | 0.24 (2.89) | 46.3% (25) | 46.88% (15) | 100% (1) | 0.57 (1.14) |
| Control − NAFLD | 51.52% (34) | 71.43% (10) | 33.33% (2) | 53.7% (29) | 53.13% (17) | 0.00% (0) | ||
|
| ||||||||
| G1422A (rs1049353) | P (chi2) | rs806381 | P (chi2) | |||||
| A/A | G/A | G/G | A/A | G/A | G/G | |||
|
| ||||||||
| PCOS + NAFLD | 48% (12) | 69.7% (23) | 64.58% (31) | 0.21 (3.05) | 72% (18) | 37.5% (9) | 66.67% (28) | 0.025 (7.36) |
| PCOS − NAFLD | 52% (13) | 30.3% (10) | 35.42% (17) | 28% (7) | 62.5% (15) | 33.33% (14) | ||
| Control + NAFLD | 33.33% (4) | 50% (14) | 48.98% (24) | 0.58 (1.07) | 45% (18) | 50% (21) | 44.44% (8) | 0.88 (0.26) |
| Control − NAFLD | 66.67% (8) | 50% (14) | 51.02% (25) | 55% (22) | 50% (21) | 55.56% (10) | ||
|
| ||||||||
| rs10485170 | P (chi2) | rs6454674 | P (chi2) | |||||
| A/A | A/G | G/G | T/T | G/T | G/G | |||
|
| ||||||||
| PCOS + NAFLD | 61.9% (52) | 45.45% (5) | 75% (6) | 0.03 (7.04) | 69.39% (34) | 48.89% (22) | 76.92% (10) | 0.06 (5.62) |
| PCOS − NAFLD | 38.1% (32) | 54.55% (6) | 25% (2) | 30.61% (15) | 51.11% (23) | 23.08% (3) | ||
| Control + NAFLD | 50% (41) | 42.86% (9) | 0% | 0.56 (0.34) | 48.98% (24) | 50% (20) | 42.86% (6) | 0.89 (0.22) |
| Control − NAFLD | 50% (41) | 57.14% (12) | 0% | 51.02% (25) | 50% (20) | 57.14% (8) | ||
PCOS + NAFLD: women with polycystic ovary syndrome and nonalcoholic fatty liver disease.
PCOS − NAFLD: women with polycystic ovary syndrome without nonalcoholic fatty liver disease.
Control + NAFLD: women from control group having nonalcoholic fatty liver disease.
Control − NAFLD: women from control group without nonalcoholic fatty liver disease.